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Abstract
Study design and aim: This was a longitudinal chart review of a diverse group (cohort) of
patients undergoing HGH (Human Growth Hormone) treatment. Clinical and radiological
examinations were performed with the aim to identify the presence and progression of scoliosis.
Methods and cohort: 185 patients were recruited and a database incorporating the age at
commencement, dose and frequency of growth hormone treatment and growth charts was
compiled from their Medical Records. The presence of any known syndrome and the clinical
presence of scoliosis were included for analysis. Subsequently, skeletally immature patients
identified with scoliosis were followed up over a period of a minimum four years and the radiologic
type, progression and severity (Cobb angle) of scoliosis were recorded.
Results: Four (3.6%) of the 109 with idiopathic short stature or hormone deficiency had idiopathic
scoliosis (within normal limits for a control population) and scoliosis progression was not
prospectively observed. 13 (28.8%) of 45 with Turner syndrome had scoliosis radiologically similar
to idiopathic scoliosis. 11 (48%) of 23 with varying syndromes, had scoliosis. In the entire cohort,
the growth rates of those with and without scoliosis were not statistically different and HGH
treatment was not ceased because of progression of scoliosis.
Conclusion: In this study, there was no evidence of HGH treatment being responsible for
progression of scoliosis in a small number of non-syndromic patients (four). An incidental finding
was that scoliosis, similar to the idiopathic type, appears to be more prevalent in Turner syndrome
than previously believed.
Background
Research indicating that juveniles who develop idiopathic
scoliosis have a markedly elevated growth rate compared
to controls fostered a popular belief that growth hormone
influences the progression of scoliosis[1,2]. Serum levels
of growth hormone in children with idiopathic scoliosis
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twelve years compared to controls [3-7]. Progression of
structural scoliosis was reported in a short-statured patient
during Human Growth Hormone (HGH) treatment [8]
and stimulated a systematic clinical audit of children with
scoliosis on an HGH treatment programme in one institu-
tion [9]. The administration of HGH appeared to acceler-
ate the progression of scoliosis in six of ten children on
that programme (cohort size 250) [9]. Of the ten, five had
idiopathic scoliosis, one had acute lymphocytic leukae-
mia and two with Turner syndrome were diagnosed with
scoliosis prior to treatment. An accelerated growth rate
was also recorded in eight of ten with scoliosis.
Armed with this information, it was hypothesized that
children with scoliosis, who are administered Human
Growth Hormone, are more likely to have progression of
their scoliosis and an accelerated growth rate compared to
those without scoliosis. The aims of this study are to deter-
mine the prevalence of scoliosis in four Australian Institu-
tions' Growth Hormone Treatment Programmes and to
confirm the results of previous research that HGH treat-




298 medical records were available for scrutiny and 30
were excluded for reasons outlined in Exclusion criteria. A
database was completed for 185 (69%) of the remaining
268 patients. 83 (31%) refused to complete the mailed-
out questionnaire and sign consent. Of the 185 patients,
97 had idiopathic short stature and 12 had either growth
hormone or multiple pituitary hormone deficiency. 68
had a condition/syndrome known to be associated with
scoliosis (Table 1). Eight patients had conditions not usu-
ally associated with scoliosis (Table 2).
Exclusion criteria
Exclusion criteria for clinical examination included five
children less than six years old and nineteen who com-
menced the OZGROW (The Australasian Paediatric
Growth Hormone database) programme over the age of
twelve years, because of their proximity to menarche. Two
Table 1: Syndromes/conditions known to be associated with scoliosis
Diagnosis Number of patients Number with scoliosis
Turner 45 14 (1 congenital)
Vater 2 2
Leri-Weill 2 2
Russell Silver dwarf 1 1






Cerebral Palsy 1 1
Spina Bifida 1 1
Multiple seizures 1 0
Cysteinosis 1 0
Fanconi Syndrome and Rickets 1 1
Pituitary Deep Xray therapy 1 1
Downs 1 1
Congenital rubella 1 0
Deep Xray therapy to the brain 4 0
Table 2: Conditions other than idiopathic short stature, not usually associated with scoliosis
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their minds were excluded. The Medical Records of four
deceased were available for perusal, but were excluded
from analysis.
Database
The age at examination, gender, growth charts (Stature for
Age – developed by the National Centre for Health Statis-
tics in conjunction with the National Centre for Chronic
Disease Prevention and Health Promotion 2000), the tim-
ing (age of commencement) and dosage and frequency of
growth hormone treatment and the presence, site and
severity of any detected spinal deformity were recorded
for all who underwent clinical examination (Additional
file 1). Turner syndrome growth charts were used specifi-
cally for that syndrome [10]. Turner syndrome karyotypes
were recorded (Table 3). Information from the medical
records revealed the presence of any known spinal
deformity prior to the commencement of the HGH treat-
ment.
Growth chart information
Actual and percentile heights were recorded at three
monthly intervals during the HGH treatment programme.
Percentile, rather than actual, heights were included for
analysis because the growth chart with actual heights for
Turner syndrome has a different scale from the National
Centre for Health Statistics scale.
Clinical confirmation of spine deformity
Patients presented dressed in a white Hospital gown for a
forward bend test (Adams), having removed their shoes
[11]. One examiner (GD) used a scoliometer to measure
for thoracic and lumbar spine rotation (Bunnell test) [12].
Patients with a straight spine and no truncal rotation were
not asked to present for spine radiographs.
Radiologic confirmation of the spine deformity
Spine radiographs of all patients with clinical signs of sco-
liosis have been performed with the exception of one with
Turner syndrome and another who had undergone deep
Xray therapy. Both were skeletally mature at the time of
clinical examination. Standard postero-anterior and lat-
eral complete spine radiographs in the erect posture were
reviewed. Images at the time of clinical examination were
in a hard-copy form and images after 2002 were in digital
format. Cobb angles were drawn by the treating scoliosis
surgeons and recorded.
Measurement of progression of scoliosis
Two patients detected with previously unrecognised spine
lateral deviation/trunk rotation were referred to the Scol-
iosis Clinic in their hospital, and subsequently underwent
spine imaging every six-months to skeletal maturity. A
third patient with previously unrecognised spine deform-
ity was skeletally mature and underwent a single spine
radiograph. Twenty-four with known scoliosis had under-
gone similar regular follow-up in Scoliosis Clinics, prior
to clinical examination in this study (two continued fol-
low-up after the 2002 clinical examination). Follow-up
spine imaging ceased when patients became skeletally
mature or Human Growth Hormone treatment ceased. An
increase in Cobb angle of 10° was the minimum measure-
ment used to define progression of scoliosis.
Ethics
Institutional Ethics approval was granted from four hospi-
tals in three Australian States to clinically examine all their
patients treated through the OZGROW program.
Statistical analysis
This study produced subgroups with data that could be
analysed using a chi-square comparison (Student's t-test).
Factors that might theoretically influence the presence or
progression of scoliosis including the age of commence-
Table 3: Turner syndrome scoliosis (non-congenital)
Scoliosis Karyotype
12° Right thoracic, hypokyphosis 45XO
30° Right Thoraco-lumbar 45XO
18° Right thoracic, hypokyphosis 46XisoX(q10) Mosaic
30° Right Thoraco-lumbar 45XO
No Xrays Mild clinical deformity Right thoracic 45XO
17° Left Thoraco-lumbar 45XO
18° Right thoracic, hypokyphosis 45XO
55° Right thoracic Scoliosis surgery 45XO
45° Right thoracic, hypokyphosis 45XO
10° Right lumbar Diagnosed South Africa. Karyotype not available.
20° Left Thoraco-lumbar 45XO
12° left Thoraco-lumbar 45XO/46XY mosaic Undiagnosed syndrome
45° Right Thoracic, hypokyphosis 45XOPage 3 of 8
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nitude of each dose/average dose of growth hormone and
the total amount of growth hormone administered to
each patient were included for analysis. Step-wise multi-
ple regression analysis used univariate models for each




At review in 2001/2002, the mean age of the patients was
13.6 years (range 6–27 years). 91 were male and 94 were
female. The mean age at commencement on the
OZGROW programme was 8.5 years (range from birth to
12 years, and followed a normal distribution). The mean
duration of HGH therapy up to the time of review was 4.7
years (range 2 months to 12 years). The findings from rou-
tine clinical and radiological follow-up for those in Scol-
iosis Clinics ceased in 2006, spanning 4–5 years duration
(mean 4.6 years).
Presence of scoliosis
29 of 185 patients had scoliosis. The duration of HGH
therapy and total dose of human growth hormone were
not related to the presence of scoliosis, although the aver-
age of the first two doses of growth hormone per patient,
expressed in milligrams per kilogram body weight, was
related to the presence of scoliosis. (p = 0.021). Having
Turner syndrome was identified as the only highly signif-
icant factor for the presence of scoliosis (p = 0.001).
Progression of scoliosis
The mean duration of HGH treatment for the entire
cohort was 4.7 years (SD 2.8). A number of different HGH
regimens were administered to the cohort including Sai-
zen™, Norditropin™, Somaton™, Genotropin™ and
Humatropin™. The mean dose of HGH treatment was
0.60 mg/Kg body weight (Range 0.25 – 1.14 mg/Kg body
weight and SD 0.227). HGH therapy was ceased and
restarted at a later stage in 13 children for reasons other
than the presence of scoliosis. One male with Cushing's
syndrome and mild thoracic scoliosis had a temporary
three-month cessation of HGH treatment. HGH therapy
was re-started and continued for another two years, with
no radiologic progression of scoliosis. Progression of sco-
liosis was not recorded in two patients with idiopathic
scoliosis and two with other conditions, followed up in
Scoliosis Clinics between 2001/2 and 2006.
Progression of scoliosis had already occurred in five
Turner and two 'other condition' patients at the time of
clinical review in 2001/2002 (Cobb angles between 30°
and 55°).
Idiopathic short stature and hormone deficiency subgroup
Four (3.4%) of the 117 in this subgroup had scoliosis. All
four had idiopathic right thoracic scoliosis less than 20
degrees Cobb angle. Three were male and all were una-
ware of their scoliosis until they were examined in this
study. Two of the males had idiopathic short stature and
the other had multiple pituitary hormone deficiency. Two
of the three were skeletally mature and the other was age
Table 4: Statistical analysis for the cohort of 185. Predictors of Scoliosis: Logistic Regression – Univariate Models Results
B S.E. Wald Sig. Exp(B)
Age Comm. .039 .067 .335 .563 1.040
Duration -.166 .099 2.814 .093 .847
Mg per Kg1 2.544 1.277 3.965 .046 12.728
Mg per Kg2 2.420 1.122 4.656 .031 11.245
Mg per Kg3 .716 2.085 .118 .731 2.046
Mg per Kg4 7.827 4.661 2.819 .093 2507.794
Last PCTL -.015 .016 .863 .353 .985
Turner syndr. -1.790 .471 14.430 <.001 .167
First PCTL_Age -.046 .076 .364 .546 .955
First_PCTL -.026 .024 1.255 .263 .974
B = Multiple regression co-efficient
S.E = Standard error
 Wald (Wald Abraham. Selected papers in statistics and probability. Stanford University Press. New York, Toronto, London. 1955.)
Sig.= Significance
Exp (B) = Risk ratio
Each variable was used in turn to predict the occurrence of scoliosis in a logistic regression model. The size of the first and second doses of HGH 
(MG per KG1 and 2) and having Turner syndrome were predictive of having scoliosis. Variables for analysis where numbers exceeded 30 –
a) Age of commencement
b) Duration of HGH treatment
c) Dose of HGH in Mg/Kg body weight
d) First percentile height at commencement of HGH treatment (PCTL)
e) Last percentile height at cessation of HGH treatment (PCTL)
f) Presence of Turner syndromePage 4 of 8
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review in the Scoliosis Clinic of his hospital for three
years. The only female in this group had growth hormone
deficiency and commenced HGH supplementation at age
three years and remained on the OZGROW programme at
age 13 years (in 2001). Both who continued clinical
review demonstrated no radiologic progression of their
scoliosis, from 2001/2 to 2006.
Turner syndrome subgroup
Of 45 with Turner syndrome, one had congenital scoliosis
and underwent scoliosis surgery at age 13. Curve progres-
sion was not recorded for this patient. Thirteen of the 45
(28.8%) had scoliosis radiologically indistinguishable
from idiopathic scoliosis (Figures 1, 2, 3). The mean age
at diagnosis of scoliosis was 13 (range 3–22 years). All
had oestrogen supplementation for delayed puberty. The
site/morphology of the scoliosis and karyotype was
recorded (Table 3). One had scoliosis prior to the com-
mencement of HGH treatment and two others were diag-
nosed with scoliosis within one year of commencing the
HGH treatment programme. The deformity subsequently
progressed in both, resulting in right thoracic curves of
45°. Another underwent surgery for the scoliosis deform-
ity, during HGH treatment. Analysis of the Turner syn-
drome subgroup revealed that they were administered a
larger average dose of growth hormone (milligrams per
kilogram body weight) (p = 0.003) and were commenced
on the OZGROW program at an earlier age (p < 0.001)
than the group comprising idiopathic short stature. The
magnitude of the scoliosis curve in Turner syndrome was
not influenced by the duration of HGH therapy.
Other syndromes known to be associated with the 
presence of scoliosis
Scoliosis was present in 11 of the other 23 (48%) with var-
ying other syndromes (Refer Table 1). One of this group
had kypho-scoliosis.
Growth velocity
There was a significant statistical correlation between the
first and last percentiles of height in the idiopathic short
stature and hormone deficiency subgroup (r = 0.514, p <
0.001) – ie. an acceleration of growth rate compared to
peers was not statistically evident on the growth charts,
between the commencement of the human growth hor-
mone treatment programme and its cessation. The growth
velocity of the four with scoliosis (mean 8.3 mm/year,
range 7.0 to 10.6) in the idiopathic short stature and hor-
mone deficiency subgroup was no different from the
other 113 in the subgroup (mean 9.0 mm/year, standard
deviation 7.53).
Discussion
Prevalence of scoliosis on the Human Growth Hormone 
treatment programme
In this study, the 97 patients with idiopathic short stature
had a similar prevalence of idiopathic scoliosis to a con-
trol Caucasian population [13] and served as a 'control'
group for comparisons with the other groups. The preva-
lence of scoliosis in this study was similar to previously
published research, involving 31,462 patients on Human
Growth Hormone treatment programmes [14-18]. Scolio-
sis is not a specific feature of idiopathic short stature and
its prevalence should mirror that of the control popula-
tion [19]. Although scoliosis has been extensively
reported in specific syndromes associated with short stat-
ure, the commonest spinal deformity in short-stature syn-
dromes and skeletal dysplasias is kyphosis [19].
Prevalence of scoliosis in Turner syndrome on the HGH 
treatment programme
The 28.8% prevalence of scoliosis in Turner syndrome
from this study was higher than previously published
research, which includes those not treated with HGH (11–
12%) [20-22]. In a previous HGH treatment study, a 'sub-
group with Turner syndrome and those with a history of
brain tumour or vertebral abnormalities had a higher
prevalence of new and/or severe scoliosis than other
groups'[15]. In a larger HGH treatment study, 72 of
24,000 children were diagnosed with scoliosis, of whom
10 had Turner syndrome [16].
Progression of scoliosis on the Growth Hormone treatment 
programme
In this study, prospective follow-up from the four with
scoliosis and idiopathic short stature/hormone deficiency
indicated that there was no progression of the scoliosis
during HGH treatment. The deformities in the current
study were mainly single curve thoracic scoliosis and the
results are similar to those of a previous study involving
four single curves [9]. In the previous study, progression
of scoliosis was associated with six double curves during
HGH treatment, however it was not stated whether there
was a temporary/permanent cessation of HGH treatment
at the time of scoliosis progression [9].
In this study, retrospective data from the Turner syndrome
patients' medical records indicated that the scoliosis
deformity progressed in five of thirteen during HGH ther-
apy and that the HGH treatment was not stopped because
of this scoliosis progression.
Growth velocity and progression of scoliosis
In this study, the growth velocity was similar in patients
with and without idiopathic scoliosis. This result contrasts
with that of a previous study, where accelerated growthPage 5 of 8
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those without scoliosis [9].
Conclusion
This study supports the contention that the administra-
tion of Human Growth Hormone to a diverse group of
short-statured children does not lead to an increased prev-
alence of scoliosis. An accelerated growth rate during
HGH treatment was not recorded in the small numbers
with idiopathic scoliosis, contrasting with the results of
the only other similar previous study. In this study,
patients on HGH treatment with progressive scoliosis had
syndromes in which the presence of scoliosis is com-
moner than an age-matched population.
A curious incidental finding was the 28.8% prevalence of
scoliosis in Turner syndrome, which could mean that sco-
liosis is commoner in Turner syndrome than previously
believed or that treating Turner syndrome girls with
human growth hormone leads to an increased prevalence
of scoliosis.
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PA plain radiograph Turner syndrome scoliosisFigure 2
PA plain radiograph Turner syndrome scoliosis.
PA plain radiograph Turner syndrome scoliosisFigure 1
PA plain radiograph Turner syndrome scoliosis.Page 6 of 8
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Lateral plain radiograph Turner syndrome scoliosis with hypokyphosisFigure 3
Lateral plain radiograph Turner syndrome scoliosis with hypokyphosis.
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